Immune Netw.  2017 Oct;17(5):317-325. 10.4110/in.2017.17.5.317.

Comparison of the Commercial QuantiFERON-CMV and Overlapping Peptide-based ELISPOT Assays for Predicting CMV Infection in Kidney Transplant Recipients

• Kwon JS
• Kim T
• Kim SM
• Sung H
• Shin S
• Kim YH
• Shin EC
• Kim SH
• Han DJ

• KMID: 2400637
• DOI: http://doi.org/10.4110/in.2017.17.5.317

Abstract

Cytomegalovirus (CMV) is one of the most important opportunistic infections in transplant recipients. Tests for CMV-specific T cell responses have been proposed to change the current risk stratification strategy using CMV assays. We evaluated the usefulness of pre-transplant CMV-specific T cell assays in kidney transplant (KT) candidates for predicting the development of CMV infection after transplantation comparing the results of the overlapping peptides (OLPs)-based enzyme-linked immunospot (ELISPOT) assay and the commercial QuantiFERON-CMV assay. We prospectively enrolled all cases of KT over a 5-month period, except donor CMV-seropositive and recipient seronegative transplants that are at highest risk of CMV infection. All the patients underwent QuantiFERON-CMV, CMV OLPs-based pp65, and immediate-early 1 (IE-1)-specific ELISPOT assays before transplantation. The primary outcome was the incidence of CMV infection at 6 months after transplant. The total of 47 KT recipients consisted of 45 living-donor KTs and 2 deceased-donor KTs. There was no association between positive QuantiFERON-CMV results and CMV infection. However, 10 of 34 patients with phosphoprotein 65 (pp65)- or IE-1-specific ELISPOT results higher than cut-off value developed CMV infections compared with none of 13 patients with results lower than cut-off value developed CMV. The OLPs-based ELISPOT assays are more useful than the QuantiFERON-CMV assay for predicting CMV infection. Patients with higher CMV-specific T cell immunity at baseline appear to be more likely to develop CMV infections after KT, suggesting that the abrupt decline in CMV-specific T cell responses after immunosuppression, or high CMV-specific T cell responses due to frequent CMV activation before KT, may promote CMV infection.

Keyword

Cytomegalovirus; Cell-mediated Immunity; Enzyme-linked immunospot assay; Interferon-gamma Release Test

MeSH Terms

Cytomegalovirus
Enzyme-Linked Immunospot Assay*
Humans
Immunity, Cellular
Immunosuppression
Incidence
Interferon-gamma Release Tests
Kidney*
Opportunistic Infections
Peptides
Prospective Studies
Tissue Donors
Transplant Recipients*
Peptides

Figure

• 

  Figure 1 Flow chart of the study. The chart indicates the number and percentage of patients with CMV episode within the group of patients with positive or negative results of assay that defined by the cut-off value obtained from ROC curve. CMV, cytomegalovirus; ROC, receiver operating characteristic; LDKT, living-donor kidney transplant; DDKT, deceased-donor kidney transplant; pp65, phosphoprotein 65; IE-1, immediate-early 1; ELISPOT, enzyme-linked immunospot.

• 

  Figure 2 Pre-transplant CMV-specific T cell responses in the patients with CMV episode. CMV-specific T cell responses were measured by stimulating PBMCs with OLPs pools of (A) pp65, (B) IE-1 in ELISPOT or (D) combination of immunodominant peptides of CMV in QuantiFERON-CMV. The combined result of (A) and (B) is represented in (C) pp65 or IE-1. In (A-C), pre-transplant CMV-specific T cell responses of the patients with post-transplant CMV episode were likely to be higher than the patients without post-transplant CMV episode. In (D), however, IFN-γ concentration was tended to lower in the patients with CMV infection. Each result was obtained by 2 repeated experiments. CMV, cytomegalovirus; PBMC, peripheral blood mononuclear cell; OLP, overlapping peptide; pp65, phosphoprotein 65; IE-1, immediate-early 1; ELISPOT, enzyme-linked immunospot; IFN, interferon.

Reference

1. Kim SH, Lee HJ, Kim SM, Jung JH, Shin S, Kim YH, Sung H, Lee SO, Choi SH, Kim YS, et al. Diagnostic usefulness of cytomegalovirus (CMV)-specific T cell immunity in predicting CMV infection after a Pilot Proof-of-Concept Study. Infect Chemother. 2015; 47:105–110.

2. Kim T, Lee YM, Lee SO, Choi SH, Kim YS, Woo JH, Sung H, Jung JH, Shin S, Kim YH, et al. Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy. Korean J Intern Med. 2016; 31:961–970.

3. Han JS, Lee SJ, Park WK, Ko YW, Kim HO, Lee SY. A survey on the cytomegalovirus antibodies in blood donors and the diseased. Korean J Blood Transfus. 1990; 1:21–34.

4. Jung J, Lee HJ, Kim SM, Kang YA, Lee YS, Chong YP, Sung H, Lee SO, Choi SH, Kim YS, et al. Diagnostic usefulness of dynamic changes of CMV-specific T-cell responses in predicting CMV infections in HCT recipients. J Clin Virol. 2017; 87:5–11.

5. Lochmanova A, Lochman I, Tomaskova H, Marsalkova P, Raszka J, Mrazek J, Dedochova J, Martinek A, Brozmanova H, Grundmann M. Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation. Transplant Proc. 2010; 42:3574–3577.

6. Cantisán S, Lara R, Montejo M, Redel J, Rodríguez-Benot A, Gutiérrez-Aroca J, González-Padilla M, Bueno L, Rivero A, Solana R, et al. Pretransplant interferon-γ secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant. 2013; 13:738–745.

7. Rittà M, Costa C, Sidoti F, Ballocco C, Ranghino A, Messina M, Biancone L, Cavallo R. Pre-transplant assessment of CMV-specific immune response by Elispot assay in kidney transplant recipients. New Microbiol. 2015; 38:329–335.

8. Forner G, Saldan A, Mengoli C, Gussetti N, Palù G, Abate D. Cytomegalovirus (CMV) enzyme-linked immunosorbent spot assay but not CMV QuantiFERON assay is a novel biomarker to determine risk of congenital CMV infection in pregnant women. J Clin Microbiol. 2016; 54:2149–2154.

9. Saldan A, Forner G, Mengoli C, Gussetti N, Palù G, Abate D. Strong cell-mediated immune response to human cytomegalovirus is associated with increased risk of fetal infection in primarily infected pregnant women. Clin Infect Dis. 2015; 61:1228–1234.

10. Distler E, Schnürer E, Wagner E, von Auer C, Plachter B, Wehler D, Huber C, Kolbe K, Meyer RG, Herr W. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation. Biol Blood Marrow Transplant. 2008; 14:1417–1424.

11. Schachtner T, Stein M, Babel N, Reinke P. The loss of BKV-specific Immunity from pretransplantation to posttransplantation identifies kidney transplant recipients at increased risk of BKV replication. Am J Transplant. 2015; 15:2159–2169.

12. Snyder LD, Chan C, Kwon D, Yi JS, Martissa JA, Copeland CA, Osborne RJ, Sparks SD, Palmer SM, Weinhold KJ. Polyfunctional T-cell signatures to predict protection from cytomegalovirus after lung transplantation. Am J Respir Crit Care Med. 2016; 193:78–85.

13. Solano C, Muñoz I, Gutiérrez A, Farga A, Prósper F, García-Conde J, Navarro D, Gimeno C. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation. J Clin Microbiol. 2001; 39:3938–3941.

14. Chiereghin A, Gabrielli L, Zanfi C, Petrisli E, Lauro A, Piccirilli G, Baccolini F, Dazzi A, Cescon M, Morelli MC, et al. Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients. Transplant Proc. 2010; 42:69–73.

15. Costa C, Astegiano S, Terlizzi ME, Sidoti F, Curtoni A, Solidoro P, Baldi S, Bergallo M, Cavallo R. Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients. Transplant Proc. 2011; 43:1159–1161.

16. Abate D, Fiscon M, Saldan A, Cofano S, Mengoli C, Sgarabotto D, d'Agostino C, Barzon L, Cusinato R, Toscano G, et al. Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection. J Clin Microbiol. 2012; 50:1974–1980.

17. Patel M, Stefanidou M, Long CB, Fazzari MJ, Tesfa L, Del Rio M, Lamour J, Ricafort R, Madan RP, Herold BC. Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients. Pediatr Transplant. 2012; 16:18–28.

18. Westall GP, Mifsud NA, Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am J Transplant. 2008; 8:1749–1754.

19. Lisboa LF, Kumar D, Wilson LE, Humar A. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation. 2012; 93:195–200.

20. Kim SH, Lee SO, Park JB, Park IA, Park SJ, Yun SC, Jung JH, Kim YH, Kim SC, Choi SH, et al. A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients. Am J Transplant. 2011; 11:1927–1935.